Profile ng asset

PL2000 · Palatin Technologies, Inc. (PTN)

Indikasyon
mga bihirang sakit sa labis na katabaan na nauugnay sa neuroendocrine (hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome)
KumpanyaPTNPalatin Technologies, Inc.

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the tre…

Nasa kalendaryo

Timeline

Pinakabago muna.

Nob 17, 2026
12:30 PM
PTNPalatin Technologies, Inc.

Isinusulong ng Palatin ang PL2000 MC4R Agonist sa Phase 1 sa Unang Kalahati ng 2027

Iba pa mula sa Palatin Technologies, Inc.

Iba pang gamot at kandidato ng parehong kumpanya na sinusubaybayan sa sektor na ito.

PL2000 · Palatin Technologies, Inc. (PTN) — FDA Timeline at Readiness Checklist | SimianX AI